TCRX Overview

TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.

Wall Street analysts forecast TCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRX is5.50 USD with a low forecast of 3.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

TScan Therapeutics Inc revenue for the last quarter amounts to 3.00M USD, increased 139.37 % YoY.

TScan Therapeutics Inc. EPS for the last quarter amounts to -0.28 USD, increased 12.00 % YoY.

TScan Therapeutics Inc (TCRX) has 194 emplpoyees as of January 31 2026.

Today TCRX has the market capitalization of 59.00M USD.